Previous research suggests that SLC19A3 is downregulated in breast cancer by hypermethylation of a CpG-rich region in its promoter.[41,42] The positive correlation between SLC19A3 and LEP expression in our study indicates its role in breast cancer progression and metastasis (Fig. 2). Here, LEP is linked to breast cancer.